文献速递支持与姑息治疗

基线疲劳与接受全身治疗的癌症患者严重毒性反应相关

Baseline Fatigue and Severe Toxic Effects in Patients With Cancer Receiving Systemic Therapy.
PubMed 文献 · JAMA Oncol · 2026-01-01

这项汇总分析纳入17项SWOG试验的7086例患者,评估基线患者报告的疲劳与治疗相关不良事件风险的关系。结果显示,基线存在疲劳的患者发生严重、危及生命及致死性毒性反应的风险显著升高,且呈现剂量反应模式。

要点

  • 基线疲劳患者严重毒性反应风险约为无疲劳者的2倍。
  • 疲劳程度越重,致死性毒性反应风险越高,重度疲劳约5倍。
  • 治疗开始时的疲劳评估可作为毒性风险的早期临床标志。

核心结论

  • 基线患者报告的疲劳与癌症治疗相关毒性反应风险增加独立相关。

研究设计与样本

  • 队列研究与汇总分析,纳入1990至2022年17项SWOG 2期和3期试验,共7086例患者。

主要发现

  • 7086例患者中2771例(39.1%)报告有一定程度或更重的基线疲劳。
  • 与无或极轻微疲劳者相比,有疲劳者严重或更重毒性反应OR为2.09(95%CI 1.58-2.78,P<.001)。
  • 危及生命或致死性毒性反应OR为1.96(95%CI 1.36-2.82,P<.001),致死性毒性反应OR为2.35(95%CI 1.07-5.19,P=.03)。
  • 报告相当多或非常多疲劳者致死性毒性反应风险约高5倍(OR 4.99,95%CI 1.84-13.51,P=.002)。
  • 结果在症状性、血液学和非血液学不良事件类别中一致。

临床怎么用

  • 治疗开始时评估患者报告的疲劳,可帮助识别毒性高风险人群并加强症状监测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Fatigue is a common symptom reported by patients with cancer, yet its role as a predictor of treatment-related toxic effects has not been well characterized. Understanding whether fatigue measured at treatment initiation may be associated with subsequent toxic effects could help guide individualized treatment planning and symptom monitoring. OBJECTIVE: To evaluate the association between baseline patient-reported fatigue and the risk of adverse events (AEs) in cancer treatment trials. DESIGN, SETTING, AND PARTICIPANTS: This cohort study and pooled analysis assessed baseline fatigue data from 17 SWOG phase 2 and 3 trials conducted from 1990 to 2022. Patients were enrolled across multiple cancer types and treatment settings. Data analysis was performed from March 1, 2023, to October 17, 2025. EXPOSURES: Baseline fatigue, classified on a 5-point Likert scale, analyzed as binary thresholds (eg, <some vs ≥some fatigue) and across fatigue severity levels. MAIN OUTCOMES AND MEASURES: Adverse events were classified using the Common Terminology Criteria for Adverse Events (CTCAE), with multiple versions mapped to version 4. Symptomatic AEs followed the Patient-Reported Outcomes-CTCAE framework; laboratory-based or measurable toxic effects were considered objective (hematologic vs nonhematologic). Primary outcomes were grade 3 or higher (severe), grade 4 or higher (life-threatening), and grade 5 (fatal) AEs. Odds ratios (ORs) were estimated using generalized estimating equations. To account for confounding, the analysis was clustered by trial and adjusted for age, sex, race, and obesity. RESULTS: Among 7086 patients (mean [SD] age, 62.1 [15.2] years; 2107 females [29.7%] and 4979 males [70.3%]) with prostate, lung, colorectal, lymphoma, breast, melanoma, ovarian, or pancreatic cancer, 103 738 AEs were reported. At baseline, 2771 participants (39.1%) reported some or more fatigue. Proportions with maximum AEs rated grade 3 or higher, grade 4 or higher, and grade 5 were 3128 participants (44.1%), 1001 (14.1%), and 62 (0.9%), respectively. Compared with those reporting no or minimal fatigue, patients with some fatigue or more had higher risks of severe or worse toxic effects (odds ratio [OR], 2.09; 95% CI, 1.58-2.78; P < .001), life-threatening or fatal toxic effects (OR, 1.96; 95% CI, 1.36-2.82; P < .001), and fatal toxic effects (OR, 2.35; 95% CI, 1.07-5.19; P = .03). A dose-response pattern was evident: patients reporting quite a lot or very much fatigue had an approximately 5-fold higher risk of fatal toxic effects (OR, 4.99; 95% CI, 1.84-13.51; P = .002). Findings were consistent across symptomatic, hematologic, and nonhematologic AE categories. CONCLUSIONS AND RELEVANCE: This cohort study found that baseline patient-reported fatigue was associated with an increased risk of cancer treatment-related toxic effects. Fatigue assessments at treatment initiation may serve as an early clinical marker of risk for toxic effects and may help inform personalized treatment strategies and symptom monitoring.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Unger JM, Fisch MJ, Jones SMW, et al. Baseline Fatigue and Severe Toxic Effects in Patients With Cancer Receiving Systemic Therapy. JAMA Oncol. 2026. PMID: 41452615. doi:10.1001/jamaoncol.2025.5549

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。